← GeneDx Holdings Corp.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($29.7m) | ($192k) | ($245.4m) | ($549.0m) | ($175.8m) | ($52.3m) | ($21.0m) | — | |
| Depreciation and amortization expense | $6.4m | $11.7m | $21.8m | $59.3m | $33.7m | $22.0m | $25.2m | $26.9m | |
| Stock-based compensation expense | $5.5m | $120.2m | $219.4m | $42.0m | ($326k) | $9.1m | $32.2m | $35.7m | |
| Impairment loss | — | $0 | $0 | $210.1m | $10.4m | $0 | $0 | — | |
| Accounts receivable | ($4.6m) | ($10.6m) | $5.5m | $5.5m | $10.3m | ($5.4m) | ($36.2m) | ($35.6m) | |
| Provision for excess and obsolete inventory | $0 | $0 | $2.1m | $1.1m | $3.9m | $180k | $135k | — | |
| Inventory | ($8.0m) | ($9.0m) | ($10.6m) | $2.4m | $975k | ($2.6m) | ($3.4m) | ($6.0m) | |
| Accounts payable and accrued expenses | $12.8m | $14.8m | $25.9m | $34.5m | ($47.0m) | ($20.5m) | $12.1m | — | |
| Purchases of property and equipment in accounts payable and accrued expenses | $818k | $447k | $761k | $0 | $134k | $2.6m | $6.3m | ($27.1m) | |
| Other | — | — | — | $2.7m | $2.4m | $3.6m | $3.2m | — | |
| Other assets and liabilities | — | — | — | ($8.5m) | ($2.5m) | $3.7m | $12.0m | — | |
| Net cash provided by (used in) operating activities | ($18.7m) |
($386k)
+97.94%
|
($190.4m)
-49221.69%
|
($319.2m)
-67.59%
|
($180.1m)
+43.56%
|
($28.5m)
+84.18%
|
$33.3m
+216.78%
|
($48.7m)
-246.37%
|
|
| Purchases of property and equipment | ($11.9m) | ($24.1m) | ($9.4m) | ($7.2m) | ($5.2m) | ($5.5m) | ($19.0m) | ($27.1m) | |
| Purchases of marketable securities | — | — | — | $0 | ($47.7m) | ($66.3m) | ($55.7m) | — | |
| Proceeds from sales of marketable securities | — | — | — | — | $0 | $601k | $2.1m | — | |
| Proceeds from maturities of marketable securities | — | — | — | $0 | $17.8m | $41.1m | $44.0m | — | |
| Net cash used in investing activities | ($15.5m) | ($442.8m) | ($20.8m) | ($141.3m) | ($43.7m) | ($30.1m) | ($61.5m) | ($38.6m) | |
| Long-term debt principal payments | $0 | ($186k) | ($1.0m) | $0 | ($2.0m) | ($497k) | ($1.2m) | — | |
| Proceeds from long-term debt | $0 | $15.9m | $0 | $0 | $48.5m | $0 | $0 | — | |
| Issuance of common stock for first OPKO Milestone Payment | — | — | — | $0 | $6.7m | $0 | $0 | $33.9m | |
| Net cash provided by financing activities | $148.0m |
$444.2m
+200.13%
|
$493.7m
+11.14%
|
$197.3m
-60.04%
|
$186.2m
-5.61%
|
$44.2m
-76.29%
|
$48.0m
+8.75%
|
$73.6m
+53.16%
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash | $113.8m | $1.1m | $282.5m | ($263.2m) | ($37.6m) | ($14.5m) | $19.8m | — | |
| Cash, cash equivalents and restricted cash, at beginning of year | $115.0m | $119.0m | $401.5m | $138.3m | $100.7m | $86.2m | $106.0m | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Change in fair value of financial liabilities | $0 | $0 | ($198.4m) | ($70.2m) | ($1.2m) | $13.4m | $1.2m | — | |
| Legal reserves | — | — | — | — | $0 | $0 | $5.6m | — | |
| Change in third party payor reserves | — | — | — | — | ($9.7m) | $607k | $2.4m | — | |
| Acquisition of business, net of cash acquired and Consideration on escrow paid for Legacy GeneDx acquisition | — | $0 | $0 | ($127.0m) | ($12.1m) | $0 | ($32.9m) | — | |
| Proceeds from sales of assets | — | — | — | $0 | $4.0m | $0 | $0 | — | |
| Development of internal-use software assets | ($3.5m) | ($7.9m) | ($11.4m) | ($7.2m) | ($461k) | $0 | $0 | — | |
| Proceeds from offerings, net of issuance costs | — | $433.9m | — | $0 | $143.0m | $46.5m | $46.7m | — | |
| Proceeds from issuance of stock pursuant to employee stock purchase plan | — | — | — | — | $0 | $497k | $3.0m | — | |
| Exercise of stock options | $0 | $0 | $1.3m | $2.9m | $285k | $394k | $2.0m | — | |
| Finance lease payoff and principal payments | — | ($4.0m) | ($3.7m) | ($3.3m) | ($3.6m) | ($2.7m) | ($2.5m) | — | |
| Cash paid for interest | $305k | $1.7m | $2.8m | $1.9m | $3.0m | $6.7m | $6.4m | — | |
| Cash paid for taxes | $0 | $0 | $349k | $1.2m | $1.5m | $1.2m | $1.3m | — | |
| Stock consideration paid pursuant to exercise of Perceptive warrant | — | — | — | — | $0 | $12.6m | $0 | — | |
| Assets acquired under capital leases obligations | — | $1.5m | $1.1m | $461k | $0 | $689k | $0 | — | |
| Lease liability from obtaining right-of-use asset | — | — | — | $0 | $637k | $0 | $0 | — |